-
Je něco špatně v tomto záznamu ?
Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations
O. Bezdicek, R. Biundo, S. Boelema, DM. Cammisuli, B. Cholerton, A. Cronin-Golomb, JC. Dalrymple-Alford, A. Duits, R. Fellows, A. Gerstenecker, H. El Hachioui, H. Horáková, J. Koerts, B. Levin, I. Liepelt-Scarfone, M. Sarno, TA. Mestre, ÁS....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, systematický přehled
PubMed
40145638
DOI
10.1002/mds.30166
Knihovny.cz E-zdroje
- MeSH
- jazyk (prostředek komunikace) * MeSH
- kognitivní dysfunkce * diagnóza etiologie MeSH
- lidé MeSH
- neuropsychologické testy * normy MeSH
- paměť * fyziologie MeSH
- Parkinsonova nemoc * komplikace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
BACKGROUND: Cognitive impairment in Parkinson's disease (PD) is a key non-motor complication during the disease course. OBJECTIVES: A review of detailed cognitive instruments to detect mild cognitive impairment (PD-MCI) or dementia (PDD) is needed to establish optimal tests that facilitate diagnostic accuracy. METHODS: We performed a systematic literature review of tests that assess memory, language including premorbid intelligence, and visuospatial domains (for tests of attention and executive functions see accompanying review) to determine suitability to assess cognition in PD. Based on in-depth scrutiny of psychometric and other relevant clinimetric properties, tests were rated as "recommended," "recommended with caveats," "suggested," or "listed" by the International Parkinson and Movement Disorder Society (IPMDS) panel of experts according to the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee guidelines. RESULTS: We included 39 tests encompassing 48 outcome measures. Seven tests (different versions or subtests of the test counted once) were recommended, including four for memory, one for visuospatial domains, one for language (including three measures), and one for estimated premorbid intelligence. Furthermore, 10 tests (12 measures) were "recommended with caveats," 11 were "suggested," and 11 (15 measures) were "listed." CONCLUSIONS: Recommended neuropsychological tests in memory, visuospatial functions, and language are proposed to guide the assessment of cognitive impairment and its progression in PD-MCI and PDD, and for use in clinical trials to stratify participants or as outcome measures. Novel measures being developed will need extensive validation research to be "recommended." © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Amsterdam Neuroscience Neurodegeneration Amsterdam The Netherlands
Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas Madrid Spain
Department of General Psychology University of Padua Padua Italy
Department of Medicine University of Otago Christchurch New Zealand
Department of Neurological Sciences Rush University Medical Center Chicago Illinois USA
Department of Neurology Safarik University Kosice Slovakia
Department of Neurology University Hospital of L Pasteur Kosice Slovakia
Department of Pathology Stanford University School of Medicine Stanford California USA
Department of Psychiatry University of California San Diego California USA
Department of Psychological and Brain Sciences Boston University Boston Massachusetts USA
Department of Psychology Catholic University of the Sacred Heart Milan Italy
German Center for Neurodegenerative Diseases Tübingen Germany
IB Hochschule Stuttgart Germany
Movement Disorders Unit Neurology Department Hospital Universitario 12 de Octubre Madrid Spain
New Zealand Brain Research Institute Christchurch New Zealand
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015890
- 003
- CZ-PrNML
- 005
- 20250731091328.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/mds.30166 $2 doi
- 035 __
- $a (PubMed)40145638
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bezdicek, Ondrej $u Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital in Prague, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000251080181 $7 xx0106259
- 245 10
- $a Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations / $c O. Bezdicek, R. Biundo, S. Boelema, DM. Cammisuli, B. Cholerton, A. Cronin-Golomb, JC. Dalrymple-Alford, A. Duits, R. Fellows, A. Gerstenecker, H. El Hachioui, H. Horáková, J. Koerts, B. Levin, I. Liepelt-Scarfone, M. Sarno, TA. Mestre, ÁS. Ferro, MH. de Siqueira Tosin, M. Skorvanek, D. Weintraub, GJ. Geurtsen, members of the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee
- 520 9_
- $a BACKGROUND: Cognitive impairment in Parkinson's disease (PD) is a key non-motor complication during the disease course. OBJECTIVES: A review of detailed cognitive instruments to detect mild cognitive impairment (PD-MCI) or dementia (PDD) is needed to establish optimal tests that facilitate diagnostic accuracy. METHODS: We performed a systematic literature review of tests that assess memory, language including premorbid intelligence, and visuospatial domains (for tests of attention and executive functions see accompanying review) to determine suitability to assess cognition in PD. Based on in-depth scrutiny of psychometric and other relevant clinimetric properties, tests were rated as "recommended," "recommended with caveats," "suggested," or "listed" by the International Parkinson and Movement Disorder Society (IPMDS) panel of experts according to the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee guidelines. RESULTS: We included 39 tests encompassing 48 outcome measures. Seven tests (different versions or subtests of the test counted once) were recommended, including four for memory, one for visuospatial domains, one for language (including three measures), and one for estimated premorbid intelligence. Furthermore, 10 tests (12 measures) were "recommended with caveats," 11 were "suggested," and 11 (15 measures) were "listed." CONCLUSIONS: Recommended neuropsychological tests in memory, visuospatial functions, and language are proposed to guide the assessment of cognitive impairment and its progression in PD-MCI and PDD, and for use in clinical trials to stratify participants or as outcome measures. Novel measures being developed will need extensive validation research to be "recommended." © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kognitivní dysfunkce $x diagnóza $x etiologie $7 D060825
- 650 12
- $a jazyk (prostředek komunikace) $7 D007802
- 650 12
- $a paměť $x fyziologie $7 D008568
- 650 12
- $a neuropsychologické testy $x normy $7 D009483
- 650 12
- $a Parkinsonova nemoc $x komplikace $7 D010300
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Biundo, Roberta $u Department of General Psychology, University of Padua, Padua, Italy $u Parkinson and Movement Disorders Unit, Study Center for Neurodegeneration (CESNE), Center for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, University of Padua, Padua, Italy $1 https://orcid.org/000000015846755X
- 700 1_
- $a Boelema, Sarai $u Amsterdam University Medical Center, University of Amsterdam, Department of Medical Psychology, Amsterdam, The Netherlands $1 https://orcid.org/0009000343419629
- 700 1_
- $a Cammisuli, Davide Maria $u Department of Psychology, Catholic University of the Sacred Heart, Milan, Italy $1 https://orcid.org/0000000283401867
- 700 1_
- $a Cholerton, Brenna $u Department of Pathology, Stanford University School of Medicine, Stanford, California, USA $1 https://orcid.org/000000022139987X
- 700 1_
- $a Cronin-Golomb, Alice $u Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts, USA $1 https://orcid.org/0000000156996204
- 700 1_
- $a Dalrymple-Alford, John C $u Te Kura Mahi ā-Hirikapo, School of Psychology, Speech and Hearing, University of Canterbury, Christchurch, New Zealand $u New Zealand Brain Research Institute, Christchurch, New Zealand $u Department of Medicine, University of Otago, Christchurch, New Zealand $1 https://orcid.org/000000026672033X
- 700 1_
- $a Duits, Annelien $u Department of Medical Psychology, Maastricht University Medical Centre and Radboud University Centre Nijmegen and the Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands $1 https://orcid.org/0000000302791806
- 700 1_
- $a Fellows, Robert $u Department of Psychiatry, University of California, San Diego, California, USA $1 https://orcid.org/0000000293224550
- 700 1_
- $a Gerstenecker, Adam $u Department of Neurology, Division of Neuropsychology, University of Alabama at Birmingham, Birmingham, Alabama, USA $1 https://orcid.org/0000000326965380
- 700 1_
- $a El Hachioui, Hanane $u Amsterdam University Medical Center, University of Amsterdam, Department of Medical Psychology, Amsterdam, The Netherlands $1 https://orcid.org/0009000136038831
- 700 1_
- $a Horáková, Hana $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000341921423
- 700 1_
- $a Koerts, Janneke $u Department of Clinical and Developmental Neuropsychology, Faculty of Behavioral and Social Sciences, University of Groningen, Groningen, The Netherlands $1 https://orcid.org/0000000223170171
- 700 1_
- $a Levin, Bonnie $u Division of Neuropsychology and Cognitive Neuroscience, Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA $1 https://orcid.org/000000030931296X
- 700 1_
- $a Liepelt-Scarfone, Inga $u Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Eberhard Karls University Tübingen, Tübingen, Germany $u German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany $u IB-Hochschule, Stuttgart, Germany $1 https://orcid.org/000000020875892X
- 700 1_
- $a Sarno, Marina $u Division of Neuropsychology and Cognitive Neuroscience, Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA $1 https://orcid.org/0000000168927775
- 700 1_
- $a Mestre, Tiago A $u Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa Brain and Mind Institute, Ottawa, Ontario, Canada $1 https://orcid.org/0000000269737479
- 700 1_
- $a Ferro, Álvaro Sánchez $u Movement Disorders Unit, Neurology Department, Hospital Universitario 12 de Octubre, Madrid, Spain $u Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain $1 https://orcid.org/0000000324612485
- 700 1_
- $a de Siqueira Tosin, Michelle Hyczy $u Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA $1 https://orcid.org/0000000173091407
- 700 1_
- $a Skorvanek, Matej $u Department of Neurology, Safarik University, Kosice, Slovakia $u Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia $1 https://orcid.org/0000000154978715 $7 xx0225963
- 700 1_
- $a Weintraub, Daniel $u Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania and Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA $1 https://orcid.org/0000000306337168
- 700 1_
- $a Geurtsen, Gert J $u Amsterdam University Medical Center, University of Amsterdam, Department of Medical Psychology, Amsterdam, The Netherlands $u Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands $1 https://orcid.org/000000022508340X
- 710 2_
- $a members of the IPMDS Clinical Outcome Assessment Scientific Evaluation Committee
- 773 0_
- $w MED00003420 $t Movement disorders $x 1531-8257 $g Roč. 40, č. 5 (2025), s. 795-806
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40145638 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091322 $b ABA008
- 999 __
- $a ok $b bmc $g 2366610 $s 1253015
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 40 $c 5 $d 795-806 $e 20250327 $i 1531-8257 $m Movement disorders $n Mov Disord $x MED00003420
- LZP __
- $a Pubmed-20250708
